Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma.
Galvani E, Mundra PA, Valpione S, Garcia-Martinez P, Smith M, Greenall J, Thakur R, Helmink B, Andrews MC, Boon L, Chester C, Gremel G, Hogan K, Mandal A, Zeng K, Banyard A, Ashton G, Cook M, Lorigan P, Wargo JA, Dhomen N, Marais R. Galvani E, et al. Among authors: wargo ja. Nat Commun. 2020 Feb 12;11(1):853. doi: 10.1038/s41467-020-14632-2. Nat Commun. 2020. PMID: 32051401 Free PMC article.
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.
Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Khalili JS, et al. Among authors: wargo ja. Clin Cancer Res. 2012 Oct 1;18(19):5329-40. doi: 10.1158/1078-0432.CCR-12-1632. Epub 2012 Jul 31. Clin Cancer Res. 2012. PMID: 22850568 Free PMC article.
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Cooper ZA, et al. Among authors: wargo ja. Cancer Immunol Res. 2014 Jul;2(7):643-54. doi: 10.1158/2326-6066.CIR-13-0215. Epub 2014 Apr 29. Cancer Immunol Res. 2014. PMID: 24903021 Free PMC article.
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C. Smith MP, et al. Among authors: wargo ja. Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003. Cancer Cell. 2016. PMID: 26977879 Free PMC article.
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Roh W, et al. Among authors: wargo ja. Sci Transl Med. 2017 Mar 1;9(379):eaah3560. doi: 10.1126/scitranslmed.aah3560. Sci Transl Med. 2017. PMID: 28251903 Free PMC article.
Hallmarks of response to immune checkpoint blockade.
Cogdill AP, Andrews MC, Wargo JA. Cogdill AP, et al. Among authors: wargo ja. Br J Cancer. 2017 Jun 27;117(1):1-7. doi: 10.1038/bjc.2017.136. Epub 2017 May 18. Br J Cancer. 2017. PMID: 28524159 Free PMC article. Review.
Interaction of molecular alterations with immune response in melanoma.
Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A, Wargo JA. Szczepaniak Sloane RA, et al. Among authors: wargo ja. Cancer. 2017 Jun 1;123(S11):2130-2142. doi: 10.1002/cncr.30681. Cancer. 2017. PMID: 28543700 Free PMC article. Review.
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.
Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C. Smith MP, et al. Among authors: wargo ja. EMBO Mol Med. 2017 Aug;9(8):1011-1029. doi: 10.15252/emmm.201607156. EMBO Mol Med. 2017. PMID: 28606996 Free PMC article.
335 results